DAX ®13.241,75+0,47%TecDAX ®2.998,92+0,73%Dow Jones27.938,04+0,56%NASDAQ 1008.301,46+0,53%

PRESS RELEASE: 4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma

| Quelle: Dow Jones Newsw... | Lesedauer etwa 5 min. | Text vorlesen Stop Pause Fortsetzen

DGAP-News: 4SC AG / Key word(s): Conference
4SC AG: Poster presentation at 1st International Symposium on Merkel Cell

2019-10-21 / 07:30
The issuer is solely responsible for the content of this announcement.

*4SC AG: Poster presentation at 1st International Symposium on Merkel Cell

· *Poster presentations at the 1st International Symposium on Merkel Cell
Carcinoma 21-22 October 2019, Tampa, Florida, USA*

_Planegg-Martinsried, Germany, 21 October 2019 -_ 4SC AG (4SC, FSE Prime
Standard: VSC) today announced that a poster entitled: The preclinical
rationale and clinical design for the combination of domatinostat with
avelumab in Merkel Cell Carcinoma patients: the MERKLIN 1 and MERKLIN 2
studies by Dr. René Bartz will be presented at the 1st International
Symposium on Merkel Cell Carcinoma 21-22 October 2019, Tampa, Florida, USA.
The poster will be available on 4SC's website [1] after the presentation.

_- Press release ends -_

*Further information*

*About 4SC*

4SC AG [2] is a clinical-stage biopharmaceutical company developing
small-molecule drugs that can target key indications in cancer with high
unmet medical needs. 4SC's pipeline is protected by a comprehensive
portfolio of patents and currently comprises two drug candidates in clinical
development: resminostat [3] and domatinostat [4].

4SC aims to generate future growth and enhance its enterprise value by
entering into partnerships with pharmaceutical and biotech companies and/or
the eventual marketing and sales of approved drugs in select territories by
4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The
Company had 47 employees as of 30 September 2019 and is listed on the Prime
Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN:

*About domatinostat*

Domatinostat [4] is an orally administered small molecule class I selective
HDAC inhibitor. It strengthens the body's own anti-tumor immune response,
influences the tumor and tumor microenvironment, making the tumor more
visible to the immune system and facilitating the infiltration of immune
cells into the tumor.

Domatinostat has been investigated in a Phase I study in 24 heavily
pretreated patients with several types of advanced hematologic cancers and
was well tolerated. Positive signs of anti-tumor efficacy were also
observed; with one complete remission (28 months) and one partial responder
(8 months).

In addition to its therapeutic potential in cancer monotherapy, 4SC is
evaluating domatinostat's capacity as a partner in combination therapies,
specifically in the immuno-oncology area. In this respect, 4SC initiated a
Phase Ib/II study of domatinostat in combination with the anti-PD-1
checkpoint inhibitor pembrolizumab in patients with advanced-stage melanoma
from which initial data was presented at ESMO 2019. A second Phase II study
of domatinostat in combination with the anti-PD-L1 checkpoint inhibitor
avelumab in patients with advanced-stage microsatellite-stable
gastrointestinal cancer is currently being conducted by Prof. David
Cunningham at The Royal Marsden NHS Foundation Trust in London, UK.

4SC also plans to advance domatinostat into a number of other studies in
combination with a checkpoint inhibitor, including in patients with advanced
Merkel-cell carcinoma (MCC), in 2019 and 2020.

*About the MERKLIN clinical studies*

The Phase II open label, multicenter MERKLIN 2 and 1 clinical studies will
be initiated by 4SC in Q4 2019 and Q1, 2020 respectively and will evaluate
the combination of domatinostat and the PD-L1 checkpoint inhibitor avelumab
in patients with advanced Merkel-cell carcinoma.

*About merkel cell carcinoma*

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cancer of the
skin prone with a high risk of metastasis and whose incidence has tripled
over the last 20 years. Risk factors for MCC include sun exposure, fair
skin, age over 50 and a weakened immune system. There are few effective
treatments for MCC, but immunotherapy with checkpoint blockade is approved
in both the EU, US and Australia based on positive data in a number of
clinical studies.

*Forward-looking information*

Information set forth in this press release contains forward-looking
statements, which involve risks and uncertainties. The forward-looking
statements contained herein represent the judgement of 4SC as of the date of
this press release. Such forward-looking statements are neither promises nor
guarantees but are subject to a variety of risks and uncertainties, many of
which are beyond 4SC's control, and which could cause actual results to
differ materially from those contemplated in these forward-looking
statements. 4SC expressly disclaims any obligation or undertaking to release
any updates or revisions to any such statements to reflect any change in its
expectations or any change in events, conditions or circumstances on which
any such statement is based.


+49 89 700763-0

2019-10-21 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Phone: +49 89 700763-0
Fax: +49 89 700763-29
E-mail: ir-pr@4sc.com
Internet: www.4sc.com
ISIN: DE000A14KL72
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
EQS News ID: 892503

End of News DGAP News Service

892503 2019-10-21

1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=7dd46c31efcb536b271b29a974e3601c&application_id=892503&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a3f798387243807b3f8a19e5b23d27d3&application_id=892503&site_id=vwd&application_name=news
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=68dc7cb74b38606df65d4ee0bab4935a&application_id=892503&site_id=vwd&application_name=news
4: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=14b02b8b1ecf184fc154a9f24cfc75aa&application_id=892503&site_id=vwd&application_name=news

(END) Dow Jones Newswires

October 21, 2019 01:30 ET ( 05:30 GMT)

Das könnte Sie auch interessieren



Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Elon Musk hat vor in der Nähe von Berlin eine Gigafabrik zu bauen. Ist das eher ein Segen für die Region und Deutschland oder eher eine Kampfansage an die deutschen Autobauer?
Jetzt abstimmen!
Alle Umfragen ansehen